Among individuals with Type 2 diabetes (T2DM), cardiovascular disease (CVD) is the leading cause of morbidity and mortality. Sex and gender differences (SGDs) in the cardiovascular consequences of T2DM are relevant suggesting the need for a more aggressive CVD preventive strategy in diabetic women as they lose the so-called "female advantage" in terms of CVD risk comparing with the nondiabetic population. Multiple factors may explain the disproportion in CVD risk among women with diabetes comparing with diabetic men or non-diabetic women. Both genetic and hormonal factors only partially explain SGDs in CVD risk in diabetes. However, women likely reach diagnosis later and in worse conditions, they undergo both diagnostic and therapeutic supports in lower percentage and, finally, they are not able to obtain therapeutic goals recommended by guidelines. Concerning the cardiovascular system, diabetes amplifies the extent of damage at both micro- and macrovascular level differently among sexes.

Sex differences in Type-2 diabetes: implications for cardiovascular risk management / Raparelli, Valeria; Morano, Susanna; Franconi, Flavia; Lenzi, Andrea; Basili, Stefania. - In: CURRENT PHARMACEUTICAL DESIGN. - ISSN 1873-4286. - 23:10(2017), pp. 1471-1476. [10.2174/1381612823666170130153704]

Sex differences in Type-2 diabetes: implications for cardiovascular risk management

RAPARELLI, Valeria;MORANO, Susanna;LENZI, Andrea;BASILI, Stefania
2017

Abstract

Among individuals with Type 2 diabetes (T2DM), cardiovascular disease (CVD) is the leading cause of morbidity and mortality. Sex and gender differences (SGDs) in the cardiovascular consequences of T2DM are relevant suggesting the need for a more aggressive CVD preventive strategy in diabetic women as they lose the so-called "female advantage" in terms of CVD risk comparing with the nondiabetic population. Multiple factors may explain the disproportion in CVD risk among women with diabetes comparing with diabetic men or non-diabetic women. Both genetic and hormonal factors only partially explain SGDs in CVD risk in diabetes. However, women likely reach diagnosis later and in worse conditions, they undergo both diagnostic and therapeutic supports in lower percentage and, finally, they are not able to obtain therapeutic goals recommended by guidelines. Concerning the cardiovascular system, diabetes amplifies the extent of damage at both micro- and macrovascular level differently among sexes.
2017
Antiplatelet therapy; Cardiovascular disease; Diabetes; Gender; Prevention; Sex; Statins; Pharmacology; Drug Discovery3003 Pharmaceutical Science
01 Pubblicazione su rivista::01a Articolo in rivista
Sex differences in Type-2 diabetes: implications for cardiovascular risk management / Raparelli, Valeria; Morano, Susanna; Franconi, Flavia; Lenzi, Andrea; Basili, Stefania. - In: CURRENT PHARMACEUTICAL DESIGN. - ISSN 1873-4286. - 23:10(2017), pp. 1471-1476. [10.2174/1381612823666170130153704]
File allegati a questo prodotto
File Dimensione Formato  
Raparelli_sex-differences_2017.pdf

accesso aperto

Tipologia: Documento in Post-print (versione successiva alla peer review e accettata per la pubblicazione)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 1.42 MB
Formato Adobe PDF
1.42 MB Adobe PDF

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/952461
Citazioni
  • ???jsp.display-item.citation.pmc??? 7
  • Scopus 15
  • ???jsp.display-item.citation.isi??? 14
social impact